Advances in Immunotherapy for Adult Glioblastoma

Despite aggressive multimodal therapy, glioblastoma (GBM) remains the most common malignant primary brain tumor in adults. With the advent of therapies that revitalize the anti-tumor immune response, several immunotherapeutic modalities have been developed for treatment of GBM. In this review, we su...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-07, Vol.13 (14), p.3400
Main Authors: Chokshi, Chirayu R., Brakel, Benjamin A., Tatari, Nazanin, Savage, Neil, Salim, Sabra K., Venugopal, Chitra, Singh, Sheila K.
Format: Article
Language:English
Subjects:
Antigens
Brain cancer
Brain tumors
Chimeric antigen receptors
Clinical trials
Cytomegalovirus
Glioblastoma
Immune checkpoint inhibitors
Immunotherapy
Lymphatic system
Lymphocytes
Lymphocytes T
Microenvironments
Monoclonal antibodies
Patients
Peptides
Proteins
Review
Tumor cells
Tumors
Vaccines
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c398t-ee0759e8ad6cd39b2fd9cc2861cafd3bb2d6d1516bc6275c127e5be861a3247c3
cites cdi_FETCH-LOGICAL-c398t-ee0759e8ad6cd39b2fd9cc2861cafd3bb2d6d1516bc6275c127e5be861a3247c3
container_end_page
container_issue 14
container_start_page 3400
container_title Cancers
container_volume 13
creator Chokshi, Chirayu R.
Brakel, Benjamin A.
Tatari, Nazanin
Savage, Neil
Salim, Sabra K.
Venugopal, Chitra
Singh, Sheila K.
description Despite aggressive multimodal therapy, glioblastoma (GBM) remains the most common malignant primary brain tumor in adults. With the advent of therapies that revitalize the anti-tumor immune response, several immunotherapeutic modalities have been developed for treatment of GBM. In this review, we summarize recent clinical and preclinical efforts to evaluate vaccination strategies, immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cells. Although these modalities have shown long-term tumor regression in subsets of treated patients, the underlying biology that may predict efficacy and inform therapy development is being actively investigated. Common to all therapeutic modalities are fundamental mechanisms of therapy evasion by tumor cells, including immense intratumoral heterogeneity, suppression of the tumor immune microenvironment and low mutational burden. These insights have led efforts to design rational combinatorial therapies that can reignite the anti-tumor immune response, effectively and specifically target tumor cells and reliably decrease tumor burden for GBM patients.
doi_str_mv 10.3390/cancers13143400
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8305609</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2554461199</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-ee0759e8ad6cd39b2fd9cc2861cafd3bb2d6d1516bc6275c127e5be861a3247c3</originalsourceid><addsrcrecordid>eNpdkc1Lw0AQxRdRbKk9ew148RK735u9CKVoLRS86HnZ7G5sSpKNu0mh_70JLaKdywy8x29meADcI_hEiIQLoxvjQkQEUUIhvAJTDAVOOZf0-s88AfMY93AoQpDg4hZMCMUy44hNAVzaw4iJSdkkm7ruG9_tXNDtMSl8SJa2r7pkXZU-r3TsfK3vwE2hq-jm5z4Dn68vH6u3dPu-3qyW29QQmXWpc1Aw6TJtubFE5riw0hg8LDW6sCTPseUWMcRzw7FgBmHhWO4GXRNMhSEz8Hzitn1eO2tc0wVdqTaUtQ5H5XWp_itNuVNf_qAyAhmHcgA8ngHBf_cudqouo3FVpRvn-6gwYwxByogYrA8X1r3vQzO8N7oo5QjJEbg4uUzwMQZX_B6DoBoDUReBkB86_X4G</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2554461199</pqid></control><display><type>article</type><title>Advances in Immunotherapy for Adult Glioblastoma</title><source>NCBI_PubMed Central（免费）</source><source>Publicly Available Content Database</source><creator>Chokshi, Chirayu R. ; Brakel, Benjamin A. ; Tatari, Nazanin ; Savage, Neil ; Salim, Sabra K. ; Venugopal, Chitra ; Singh, Sheila K.</creator><creatorcontrib>Chokshi, Chirayu R. ; Brakel, Benjamin A. ; Tatari, Nazanin ; Savage, Neil ; Salim, Sabra K. ; Venugopal, Chitra ; Singh, Sheila K.</creatorcontrib><description>Despite aggressive multimodal therapy, glioblastoma (GBM) remains the most common malignant primary brain tumor in adults. With the advent of therapies that revitalize the anti-tumor immune response, several immunotherapeutic modalities have been developed for treatment of GBM. In this review, we summarize recent clinical and preclinical efforts to evaluate vaccination strategies, immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cells. Although these modalities have shown long-term tumor regression in subsets of treated patients, the underlying biology that may predict efficacy and inform therapy development is being actively investigated. Common to all therapeutic modalities are fundamental mechanisms of therapy evasion by tumor cells, including immense intratumoral heterogeneity, suppression of the tumor immune microenvironment and low mutational burden. These insights have led efforts to design rational combinatorial therapies that can reignite the anti-tumor immune response, effectively and specifically target tumor cells and reliably decrease tumor burden for GBM patients.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13143400</identifier><identifier>PMID: 34298615</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Antigens ; Brain cancer ; Brain tumors ; Chimeric antigen receptors ; Clinical trials ; Cytomegalovirus ; Glioblastoma ; Immune checkpoint inhibitors ; Immunotherapy ; Lymphatic system ; Lymphocytes ; Lymphocytes T ; Microenvironments ; Monoclonal antibodies ; Patients ; Peptides ; Proteins ; Review ; Tumor cells ; Tumors ; Vaccines ; Vascular endothelial growth factor</subject><ispartof>Cancers, 2021-07, Vol.13 (14), p.3400</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-ee0759e8ad6cd39b2fd9cc2861cafd3bb2d6d1516bc6275c127e5be861a3247c3</citedby><cites>FETCH-LOGICAL-c398t-ee0759e8ad6cd39b2fd9cc2861cafd3bb2d6d1516bc6275c127e5be861a3247c3</cites><orcidid>0000-0003-1388-3490</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2554461199/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2554461199?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids></links><search><creatorcontrib>Chokshi, Chirayu R.</creatorcontrib><creatorcontrib>Brakel, Benjamin A.</creatorcontrib><creatorcontrib>Tatari, Nazanin</creatorcontrib><creatorcontrib>Savage, Neil</creatorcontrib><creatorcontrib>Salim, Sabra K.</creatorcontrib><creatorcontrib>Venugopal, Chitra</creatorcontrib><creatorcontrib>Singh, Sheila K.</creatorcontrib><title>Advances in Immunotherapy for Adult Glioblastoma</title><title>Cancers</title><description>Despite aggressive multimodal therapy, glioblastoma (GBM) remains the most common malignant primary brain tumor in adults. With the advent of therapies that revitalize the anti-tumor immune response, several immunotherapeutic modalities have been developed for treatment of GBM. In this review, we summarize recent clinical and preclinical efforts to evaluate vaccination strategies, immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cells. Although these modalities have shown long-term tumor regression in subsets of treated patients, the underlying biology that may predict efficacy and inform therapy development is being actively investigated. Common to all therapeutic modalities are fundamental mechanisms of therapy evasion by tumor cells, including immense intratumoral heterogeneity, suppression of the tumor immune microenvironment and low mutational burden. These insights have led efforts to design rational combinatorial therapies that can reignite the anti-tumor immune response, effectively and specifically target tumor cells and reliably decrease tumor burden for GBM patients.</description><subject>Antigens</subject><subject>Brain cancer</subject><subject>Brain tumors</subject><subject>Chimeric antigen receptors</subject><subject>Clinical trials</subject><subject>Cytomegalovirus</subject><subject>Glioblastoma</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunotherapy</subject><subject>Lymphatic system</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Microenvironments</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Peptides</subject><subject>Proteins</subject><subject>Review</subject><subject>Tumor cells</subject><subject>Tumors</subject><subject>Vaccines</subject><subject>Vascular endothelial growth factor</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkc1Lw0AQxRdRbKk9ew148RK735u9CKVoLRS86HnZ7G5sSpKNu0mh_70JLaKdywy8x29meADcI_hEiIQLoxvjQkQEUUIhvAJTDAVOOZf0-s88AfMY93AoQpDg4hZMCMUy44hNAVzaw4iJSdkkm7ruG9_tXNDtMSl8SJa2r7pkXZU-r3TsfK3vwE2hq-jm5z4Dn68vH6u3dPu-3qyW29QQmXWpc1Aw6TJtubFE5riw0hg8LDW6sCTPseUWMcRzw7FgBmHhWO4GXRNMhSEz8Hzitn1eO2tc0wVdqTaUtQ5H5XWp_itNuVNf_qAyAhmHcgA8ngHBf_cudqouo3FVpRvn-6gwYwxByogYrA8X1r3vQzO8N7oo5QjJEbg4uUzwMQZX_B6DoBoDUReBkB86_X4G</recordid><startdate>20210707</startdate><enddate>20210707</enddate><creator>Chokshi, Chirayu R.</creator><creator>Brakel, Benjamin A.</creator><creator>Tatari, Nazanin</creator><creator>Savage, Neil</creator><creator>Salim, Sabra K.</creator><creator>Venugopal, Chitra</creator><creator>Singh, Sheila K.</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1388-3490</orcidid></search><sort><creationdate>20210707</creationdate><title>Advances in Immunotherapy for Adult Glioblastoma</title><author>Chokshi, Chirayu R. ; Brakel, Benjamin A. ; Tatari, Nazanin ; Savage, Neil ; Salim, Sabra K. ; Venugopal, Chitra ; Singh, Sheila K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-ee0759e8ad6cd39b2fd9cc2861cafd3bb2d6d1516bc6275c127e5be861a3247c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens</topic><topic>Brain cancer</topic><topic>Brain tumors</topic><topic>Chimeric antigen receptors</topic><topic>Clinical trials</topic><topic>Cytomegalovirus</topic><topic>Glioblastoma</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunotherapy</topic><topic>Lymphatic system</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Microenvironments</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Peptides</topic><topic>Proteins</topic><topic>Review</topic><topic>Tumor cells</topic><topic>Tumors</topic><topic>Vaccines</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chokshi, Chirayu R.</creatorcontrib><creatorcontrib>Brakel, Benjamin A.</creatorcontrib><creatorcontrib>Tatari, Nazanin</creatorcontrib><creatorcontrib>Savage, Neil</creatorcontrib><creatorcontrib>Salim, Sabra K.</creatorcontrib><creatorcontrib>Venugopal, Chitra</creatorcontrib><creatorcontrib>Singh, Sheila K.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest research library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chokshi, Chirayu R.</au><au>Brakel, Benjamin A.</au><au>Tatari, Nazanin</au><au>Savage, Neil</au><au>Salim, Sabra K.</au><au>Venugopal, Chitra</au><au>Singh, Sheila K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advances in Immunotherapy for Adult Glioblastoma</atitle><jtitle>Cancers</jtitle><date>2021-07-07</date><risdate>2021</risdate><volume>13</volume><issue>14</issue><spage>3400</spage><pages>3400-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Despite aggressive multimodal therapy, glioblastoma (GBM) remains the most common malignant primary brain tumor in adults. With the advent of therapies that revitalize the anti-tumor immune response, several immunotherapeutic modalities have been developed for treatment of GBM. In this review, we summarize recent clinical and preclinical efforts to evaluate vaccination strategies, immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cells. Although these modalities have shown long-term tumor regression in subsets of treated patients, the underlying biology that may predict efficacy and inform therapy development is being actively investigated. Common to all therapeutic modalities are fundamental mechanisms of therapy evasion by tumor cells, including immense intratumoral heterogeneity, suppression of the tumor immune microenvironment and low mutational burden. These insights have led efforts to design rational combinatorial therapies that can reignite the anti-tumor immune response, effectively and specifically target tumor cells and reliably decrease tumor burden for GBM patients.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34298615</pmid><doi>10.3390/cancers13143400</doi><orcidid>https://orcid.org/0000-0003-1388-3490</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2021-07, Vol.13 (14), p.3400
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8305609
source NCBI_PubMed Central（免费）; Publicly Available Content Database
subjects Antigens
Brain cancer
Brain tumors
Chimeric antigen receptors
Clinical trials
Cytomegalovirus
Glioblastoma
Immune checkpoint inhibitors
Immunotherapy
Lymphatic system
Lymphocytes
Lymphocytes T
Microenvironments
Monoclonal antibodies
Patients
Peptides
Proteins
Review
Tumor cells
Tumors
Vaccines
Vascular endothelial growth factor
title Advances in Immunotherapy for Adult Glioblastoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A22%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advances%20in%20Immunotherapy%20for%20Adult%20Glioblastoma&rft.jtitle=Cancers&rft.au=Chokshi,%20Chirayu%20R.&rft.date=2021-07-07&rft.volume=13&rft.issue=14&rft.spage=3400&rft.pages=3400-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13143400&rft_dat=%3Cproquest_pubme%3E2554461199%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c398t-ee0759e8ad6cd39b2fd9cc2861cafd3bb2d6d1516bc6275c127e5be861a3247c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2554461199&rft_id=info:pmid/34298615&rfr_iscdi=true